{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:02:07Z","timestamp":1790344927434,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.lungcan.2026.109486","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:27:26Z","timestamp":1780720046000},"page":"109486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study"],"prefix":"10.1016","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-1424","authenticated-orcid":false,"given":"Terufumi","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8188-2505","authenticated-orcid":false,"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nopadol","family":"Soparattanapaisarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarayut Lucien","family":"Geater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8960-7519","authenticated-orcid":false,"given":"Edurne","family":"Arriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2544-9042","authenticated-orcid":false,"given":"Fedor","family":"Moiseenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Grainger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Armenteros-Monterroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azura","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Bolanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh S.","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-7262","authenticated-orcid":false,"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.lungcan.2026.109486_b0005","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2026.109486_b0010","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","author":"Reungwetwattana","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109486_b0015","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.annonc.2025.08.003","article-title":"Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","author":"Zer","year":"2025","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109486_b0020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109486_b0025","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.22.00051","article-title":"Adjuvant systemic therapy and adjuvant radiation therapy for stage I-IIIA completely resected non-small-cell lung cancer: ASCO Guideline Rapid Recommendation Update","volume":"40","author":"Pisters","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"#cr-split#-10.1016\/j.lungcan.2026.109486_b0030.1","doi-asserted-by":"crossref","unstructured":"I.A. Jaiyesimi, N.B. Leighl, N. Ismaila, et al, Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO Living Guideline, version 2023.3, J. Clin. Oncol. 42","DOI":"10.1200\/JCO.22.02782"},{"key":"#cr-split#-10.1016\/j.lungcan.2026.109486_b0030.2","doi-asserted-by":"crossref","unstructured":"(11) (2024) e1-e22. doi: 10.1200\/jco.23.02744.","DOI":"10.1200\/JCO.23.02744"},{"key":"#cr-split#-10.1016\/j.lungcan.2026.109486_b0035.1","unstructured":"L.E. Hendriks, F. Cortiula, E. Mariamidze, et al, ESMO oncogene-addicted non-small cell lung cancer Living Guideline, v1.2 - January 2025, Ann. Oncol. 34"},{"key":"#cr-split#-10.1016\/j.lungcan.2026.109486_b0035.2","doi-asserted-by":"crossref","unstructured":"(4) (2023) 339-57. doi:10.1016\/j.annonc.2022.12.009.","DOI":"10.1016\/j.annonc.2022.12.009"},{"issue":"25","key":"10.1016\/j.lungcan.2026.109486_b0040","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1200\/JCO-24-01324","article-title":"Management of stage III non\u2013small cell lung cancer: ASCO Guideline Rapid Recommendation Update","volume":"42","author":"Daly","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109486_b0045","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109486_b0050","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.jtho.2021.05.019","article-title":"Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced NSCLC with EGFR mutation; West Japan Oncology Group 6911L","volume":"16","author":"Akamatsu","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109486_b0055","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.ijrobp.2020.11.026","article-title":"Erlotinib versus etoposide\/cisplatin with radiation therapy in unresectable stage III epidermal growth factor receptor mutation-positive non-small cell lung cancer: a multicenter, randomized, open-label, phase 2 trial","volume":"109","author":"Xing","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2026.109486_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107414","article-title":"Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: emerging evidence and future perspectives","volume":"187","author":"Kato","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109486_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102246","article-title":"Comparison of post-chemoradiotherapy pneumonitis between asian and non-asian patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"64","author":"Liu","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"20","key":"10.1016\/j.lungcan.2026.109486_b0070","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109486_b0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.lungcan.2026.109486_b0080","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109486_b0085","unstructured":"International Association for the Study of Lung Cancer (IASLC). Rami-Porta R, ed. IASLC Staging Manual in Thoracic Oncology. 2nd ed. North Fort Myers, FL: Editorial Rx Press, 2016. https:\/\/s3.us-east-1.amazonaws.com\/fonteva-customer-media\/00D3i000000D3mbEAC\/qpDjqzbp_8th_staging_manual_2016_hi_res_pdf. (Accessed November 2025)."},{"key":"10.1016\/j.lungcan.2026.109486_b0090","unstructured":"U.S. Food and Drug Administration, TAGRISSO\u00ae (osimertinib). Highlights of Prescribing Information., 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/208065s033lbl.pdf. (Accessed November 2025."},{"key":"10.1016\/j.lungcan.2026.109486_b0095","article-title":"Real-world data with afatinib in spanish patients with treatment-na\u00efve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): clinical experience of the Galician Lung Cancer Group","volume":"33","author":"Agraso","year":"2022","journal-title":"Cancer Treat Res Commun."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109486_b0100","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jtho.2023.05.015","article-title":"Three-year safety, tolerability, and health-related quality of life outcomes of adjuvant osimertinib in patients with resected stage IB to IIIA EGFR-mutated NSCLC: updated analysis from the phase 3 ADAURA trial","volume":"18","author":"John","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109486_b0105","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/clinpract11030056","article-title":"Radiation-induced lung injury-current perspectives and management","volume":"11","author":"Rahi","year":"2021","journal-title":"Clin Pract."},{"issue":"18","key":"10.1016\/j.lungcan.2026.109486_b0110","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1002\/cam4.3306","article-title":"Real-world outcomes of chemoradiotherapy for unresectable stage III non-small cell lung cancer: the SOLUTION study","volume":"9","author":"Horinouchi","year":"2020","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109486_b0115","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13014-020-01596-2","article-title":"Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial","volume":"15","author":"Fu","year":"2020","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.lungcan.2026.109486_b0120","doi-asserted-by":"crossref","unstructured":"J. Vansteenkiste, J. Naidoo, C. Faivre-Finn, et al, MA05.02 PACIFIC subgroup analysis: pneumonitis in stage III, unresectable NSCLC patients treated with durvalumab vs. placebo after CRT, J Thorac Oncol. 13 (10) (2018) S370-S71. doi: 10.1016\/j.jtho.2018.08.350.","DOI":"10.1016\/j.jtho.2018.08.350"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109486_b0125","article-title":"Symptomatic pneumonitis with durvalumab after concurrent chemoradiotherapy in unresectable stage III NSCLC","volume":"5","author":"Vansteenkiste","year":"2024","journal-title":"JTO Clin Res Rep."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:28:11Z","timestamp":1790342891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226005477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"alternative-id":["S0169500226005477"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109486","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109486","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109486"}}